CRBU
Companies
NASDAQ
Caribou Biosciences Inc.
Health Care
$1.28
-$0.31 (-19.50%)
Price Chart
Overview
About CRBU
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Market Cap
$176.1M
Volume
1.2M
Avg. Volume
1.3M
P/E Ratio
-0.5527638
Dividend Yield
0.00%
Employees
135.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.17
Moderate Correlation
Volatility
High (0.77)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CRBU shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$176.1M
Volume1.2M
P/E Ratio-0.55
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 12, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025